CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+14.84%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.34B
AUM Growth
+$1.34B
(+1.6%)
Cap. Flow
-$68.7M
Cap. Flow
% of AUM
-5.12%
Top 10 Holdings %
Top 10 Hldgs %
67.96%
Holding
45
New
3
Increased
4
Reduced
16
Closed
3
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$33.1M |
| 2 |
Merus
MRUS
|
$20M |
| 3 |
Cabaletta Bio
CABA
|
$7.6M |
| 4 |
VYNE Therapeutics
VYNE
|
$2.26M |
| 5 |
Edgewise Therapeutics
EWTX
|
$1.97M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$17.3M |
| 2 |
Arcellx
ACLX
|
$16.5M |
| 3 |
Axsome Therapeutics
AXSM
|
$15.7M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$11.8M |
| 5 |
Janux Therapeutics
JANX
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTSR
26
Metsera, Inc. Common Stock
MTSR
$3.75B
| $11.4M | 0.85% |
400,000
| – | – |
|
|
AARD
27
Aardvark Therapeutics, Inc. Common Stock
AARD
$177M
| $10.8M | 0.81% |
800,189
| – | – |
|
|
28
Axsome Therapeutics
AXSM
$6.09B
| $10.4M | 0.78% |
100,000
-150,000
| -60% | -$15.7M |
|
|
BIOA
29
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $8.84M | 0.66% |
2,140,605
-488,924
| -19% | -$2.02M |
|
30
enGene Holdings
ENGN
$249M
| $8.46M | 0.63% |
2,323,595
| – | – |
|
|
MBX
31
MBX Biosciences, Inc. Common Stock
MBX
$484M
| $7.99M | 0.59% |
700,000
| – | – |
|
|
32
Cabaletta Bio
CABA
$144M
| $7.6M | 0.57% |
+5,000,000
| New | +$7.6M |
|
|
ALMS
33
Alumis Inc. Common Stock
ALMS
$483M
| $6.44M | 0.48% |
2,147,396
| – | – |
|
34
Biomea Fusion
BMEA
$114M
| $6.43M | 0.48% |
3,570,872
| – | – |
|
35
Korro Bio
KRRO
$245M
| $5.81M | 0.43% |
465,000
+84,697
| +22% | +$1.06M |
|
36
Vaxcyte
PCVX
$4.17B
| $5.69M | 0.42% |
175,000
| – | – |
|
37
Avidity Biosciences
RNA
$6.12B
| $5.68M | 0.42% |
200,000
-200,000
| -50% | -$5.68M |
|
38
Enliven Therapeutics
ELVN
$1.24B
| $4.01M | 0.3% |
200,000
-50,000
| -20% | -$1M |
|
39
Stoke Therapeutics
STOK
$1.08B
| $2.88M | 0.21% |
254,161
| – | – |
|
40
KALA BIO
KALA
$105M
| $2.87M | 0.21% |
603,027
| – | – |
|
|
41
VYNE Therapeutics
VYNE
$8.09M
| $2.26M | 0.17% |
+1,370,938
| New | +$2.26M |
|
42
Biohaven
BHVN
$1.71B
| $141K | 0.01% |
10,000
| – | – |
|
|
OKUR
43
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| – | – |
-1,837,739
| Closed | -$7.9M |
|
44
Rhythm Pharmaceuticals
RYTM
$6.75B
| – | – |
-150,000
| Closed | -$7.95M |
|
45
Pliant Therapeutics
PLRX
$105M
| – | – |
-3,000,000
| Closed | -$4.05M |
|